Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Penn team spotlights a pilot ovarian cancer trial and survival rates for a personalized cancer vaccine
8 years ago
R&D
Discovery
Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics
8 years ago
People
Peer Review
Next-generation sequencing: FDA offers guidance to streamline path to market
8 years ago
Pharma
As gene editing explodes, a new report from Goldman says Chinese groups are seizing the lead on CRISPR and CAR-T ...
8 years ago
China
Pfizer launches a gene therapy study for Duchenne MD; Amgen, NEA back real-world drug data software company
8 years ago
News Briefing
FDA launches criminal probe into unauthorized herpes vaccine R&D backed by Peter Thiel
8 years ago
People
Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes
8 years ago
Bioregnum
Pharma
Former Novo chairman Göran Ando joins the board as Tessa bags $50M in additional funding
8 years ago
Financing
Continuing an R&D revamp, GlaxoSmithKline hands off its rare disease unit to Orchard Therapeutics
8 years ago
R&D
VC believers back a $41M game plan for Enterprise Therapeutics' new group of respiratory drugs
8 years ago
Financing
Startups
Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets
8 years ago
People
Startups
Bellicum shares surge as FDA lifts a clinical hold on lead cell therapy following a protocol adjustment
8 years ago
R&D
Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs
8 years ago
Deals
CymaBay shares soar on trial update; Lonza opens massive Texas facility dedicated to cell, gene therapies; Inovio ...
8 years ago
News Briefing
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
8 years ago
R&D
Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?
8 years ago
Deals
Pharma
Amgen goes back to Rhode Island to build its first next-gen manufacturing site in the US
8 years ago
Pharma
Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout
8 years ago
Deals
More than 2 years after the ugly roci debacle, Clovis says that the SEC is prepping civil charges
8 years ago
Pharma
Pfizer’s PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes
8 years ago
R&D
Biotech resurrects a long faded Novartis cancer drug star, using a biomarker strategy to push ahead
8 years ago
Pharma
Pfizer heads to the Hudson, signs 20-year lease at posh new NYC headquarters
8 years ago
Pharma
Tapping a biotech boom, China gene editing CRO Biocytogen bags $65M round for global expansion
8 years ago
Financing
Outsourcing
Frazier adds $780M fund for its ‘growth buyout’ team; FDA pushes back its deadline on AbbVie's elagolix; ...
8 years ago
News Briefing
First page
Previous page
1061
1062
1063
1064
1065
1066
1067
Next page
Last page